Press Releases | Medtronic

Month Year

Email alerts

Oct 29, 2012

First Results from Medtronic Engager European Pivotal Trial Demonstrate Positive Outcomes

Data Demonstrate High Procedural Success in Late-Breaking Trials Session at the European Association for Cardio-Thoracic Surgery Annual Meeting

MINNEAPOLIS - October 29, 2012 - Medtronic, Inc. (NYSE: MDT) today announced promising data from the EngagerTM European Pivotal Trial for the investigational Medtronic EngagerTM Transcatheter...
Sep 27, 2012

Medtronic Signs Agreement to Acquire China Kanghui Holdings

Acquisition Advances Medtronic's Globalization Strategy; Provides Strong Local China Operation as well as Broader Orthopedics Participation

MINNEAPOLIS and CHANGZHOU, CHINA - Sept. 27, 2012 - Medtronic, Inc. (NYSE: MDT) and China Kanghui Holdings (NYSE: KH) announced today that they have entered into a merger agreement whereby...
Sep 13, 2012

Medtronic Named a World Leader in Sustainability

MINNEAPOLIS - Sept. 13, 2012 - Medtronic, Inc. (NYSE: MDT) today was named one of the world's leading sustainability companies by its inclusion in the Dow Jones Sustainability World Index (DJSI...
Sep 12, 2012

Medtronic CFO Gary Ellis to Speak at UBS Global Lifesciences Conference

MINNEAPOLIS - Sept 12, 2012 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the UBS Global Life Sciences Conference on...
Sep 12, 2012

Health-Economic Analysis Suggests Medtronic Symplicity(TM) Renal Denervation System Is Cost-Effective and May Reduce Cardiovascular Event Risks for Patients with Treatment-Resistant Hypertension

Findings Published in The Journal of the American College of Cardiology Suggest Renal Denervation Could Substantially Reduce Cardiovascular Morbidity and Mortality for Patients with a Condition that Affects 120 Million People

MINNEAPOLIS - September 12, 2012 - Medtronic, Inc. (NYSE: MDT) today announced findings from a health-economic analysis published online before print in The Journal of the American College of...
Aug 27, 2012

Five-Year Analysis of Pivotal REVERSE Trial Demonstrates Long-Term Clinical Benefits of Medtronic CRT-D Therapy in Mild Heart Failure Patients

Low Mortality and Heart Failure Hospitalization Sustained at 5-Years Post Implant with Medtronic CRT-D Devices

MUNICH, GERMANY – August 27, 2012 – Medtronic, Inc. (NYSE: MDT) today announced findings from a new clinical analysis of the pivotal REVERSE (Resynchronization Reverse Remodeling in Systolic...
Aug 24, 2012

Medtronic Receives FDA Approval, CE Mark for Arctic Front Advance™ Cardiac Cryoballoon to Treat Atrial Fibrillation

Next-Generation Technology Reinforces Safety and Efficacy While Improving Procedure Efficiency

MINNEAPOLIS – Aug. 24, 2012 – Medtronic, Inc. (NYSE:MDT) today announced that its Arctic Front Advance™ Cardiac Cryoballoon has received both U.S. Food and Drug Administration (FDA) approval...
Aug 23, 2012

Medtronic Announces Cash Dividend for Second Quarter of Fiscal Year 2013

MINNEAPOLIS - August 23, 2012 - The board of directors of Medtronic, Inc. (NYSE:MDT) today approved a cash dividend of $0.26 per share of the company's common stock. The quarterly dividend...
Aug 21, 2012

Medtronic Reports First Quarter Earnings

Revenue of $4.0 Billion Grew 5% on a Constant Currency Basis; 2% as Reported

MINNEAPOLIS - August 21, 2012 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its first quarter of fiscal year 2013, which ended July 27, 2012. The Company reported worldwide...
Jun 21, 2012

Medtronic Stent Graft Chosen by U.S. FDA for Innovative Program

Regulatory Agency Selects Investigational Medical Device for Endovascular Treatment of Thoracic Aortic Aneurysms Involving Branch Vessel for Early Feasibility Pilot Program

MINNEAPOLIS -- June 21, 2012 -- The U.S. Food and Drug Administration (FDA) recently selected a stent graft being developed by Medtronic, Inc. (NYSE: MDT) for an early feasibility pilot program...

Show per page